Notably, these drugs interfere with pro-inflammatory signaling or viral replication to combat COVID-19. An intervention strategy that integrates various therapeutic modalities into one nanosystem could further improve the effectiveness of NP-based rugs against SARS-CoV-2 and its variants. In addition, NP-enabled nucleic acid drugs could be co-loaded with broad-spectrum antivirals in one nanosystem.
Not only nanoparticles (NPs) have shown promise as drug delivery, but formulated nanomedicines might achieve passive and active SARS-CoV-2 targeting, prolong drug circulation time and reduce side effects. For instance, some NPs primarily accrue in macrophages, raising the possibility of targeting dexamethasone to the immune cells, which, in turn, could suppress the abnormal hyper-inflammatory responses related to COVID-19. Nanotechnology-based vaccines, drugs, and antibodiesĪnti-inflammatory drugs (e.g., dexamethasone) and broad-spectrum antiviral drugs remain promising for treating coronavirus disease 2019 (COVID-19) and reducing morbidity and mortality. mRNA vaccine manufacturing companies have started to consider developing Omicron-specific vaccines. Omicron, for instance, has severely reduced the function of the neutralizing antibodies (nAbs) with less than 3% mutations in its spike (S) protein. Nanotechnology-based messenger ribonucleic acid (mRNA) vaccines have remarkably combated SARS-CoV-2 so far however, the emerging SARS-CoV-2 variants call for new strategies to compensate for the loss of mRNA vaccine efficacy against them. Image Credit: Anusorn Nakdee/Shutterstock Background
Study: Nanotechnology-based strategies against SARS-CoV-2 variants.
In a recent study published in Nature Nanotechnology, researchers explored how effectively nanotechnology-based novel and potential vaccines, drugs, and monoclonal antibodies (mAbs) could combat the current and yet to emerge severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. By Neha Mathur Reviewed by Aimee Molineux
0 kommentar(er)
